These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 25339775)

  • 21. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.
    Zeuzem S; Buggisch P; Agarwal K; Marcellin P; Sereni D; Klinker H; Moreno C; Zarski JP; Horsmans Y; Mo H; Arterburn S; Knox S; Oldach D; McHutchison JG; Manns MP; Foster GR
    Hepatology; 2012 Mar; 55(3):749-58. PubMed ID: 22006408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiviral Effect of Ribavirin against HCV Associated with Increased Frequency of G-to-A and C-to-U Transitions in Infectious Cell Culture Model.
    Galli A; Mens H; Gottwein JM; Gerstoft J; Bukh J
    Sci Rep; 2018 Mar; 8(1):4619. PubMed ID: 29545599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or Ent1-/- mouse erythrocytes.
    Endres CJ; Moss AM; Ke B; Govindarajan R; Choi DS; Messing RO; Unadkat JD
    J Pharmacol Exp Ther; 2009 Apr; 329(1):387-98. PubMed ID: 19164463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adenosine kinase is a key determinant for the anti-HCV activity of ribavirin.
    Mori K; Hiraoka O; Ikeda M; Ariumi Y; Hiramoto A; Wataya Y; Kato N
    Hepatology; 2013 Oct; 58(4):1236-44. PubMed ID: 23532970
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients.
    Funk EK; Shaffer A; Shivakumar B; Sneller M; Polis MA; Masur H; Heytens L; Nelson A; Kwan R; Kottilil S; Kohli A
    AIDS Res Hum Retroviruses; 2013 Sep; 29(9):1190-4. PubMed ID: 23701022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection.
    Pawlotsky JM; Flisiak R; Sarin SK; Rasenack J; Piratvisuth T; Chuang WL; Peng CY; Foster GR; Shah S; Wedemeyer H; Hézode C; Zhang W; Wong KA; Li B; Avila C; Naoumov NV;
    Hepatology; 2015 Oct; 62(4):1013-23. PubMed ID: 26118427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inosine Triphosphate Pyrophosphatase Dephosphorylates Ribavirin Triphosphate and Reduced Enzymatic Activity Potentiates Mutagenesis in Hepatitis C Virus.
    Nyström K; Wanrooij PH; Waldenström J; Adamek L; Brunet S; Said J; Nilsson S; Wind-Rotolo M; Hellstrand K; Norder H; Tang KW; Lagging M
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30045981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of ribavirin uptake systems in human hepatocytes.
    Fukuchi Y; Furihata T; Hashizume M; Iikura M; Chiba K
    J Hepatol; 2010 Apr; 52(4):486-92. PubMed ID: 20185188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sustained viral response and treatment-induced cytopenia correlate with SLCs and KLF12 genotypes in interferon/ribavirin-treated Chinese chronic hepatitis C patients.
    Mei R; Chi X; Wu R; Xu H; Wang X; Gao X; Sun H; Lv J; Yu G; Kong F; Jiang J; Sun B; Zhong J; Pan Y; Niu J
    J Gastroenterol Hepatol; 2016 Aug; 31(8):1489-97. PubMed ID: 26750805
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Silibinin inhibits hepatitis C virus entry into hepatocytes by hindering clathrin-dependent trafficking.
    Blaising J; Lévy PL; Gondeau C; Phelip C; Varbanov M; Teissier E; Ruggiero F; Polyak SJ; Oberlies NH; Ivanovic T; Boulant S; Pécheur EI
    Cell Microbiol; 2013 Nov; 15(11):1866-82. PubMed ID: 23701235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy.
    Saito Y; Imamura M; Uchida T; Osawa M; Teraoka Y; Fujino H; Nakahara T; Ono A; Murakami E; Kawaoka T; Miki D; Tsuge M; Serikawa M; Aikata H; Abe-Chayama H; Hayes CN; Chayama K
    J Med Virol; 2020 Feb; 92(2):210-218. PubMed ID: 31584207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNA let-7g cooperates with interferon/ribavirin to repress hepatitis C virus replication.
    Chou WW; Huang CF; Yeh ML; Tsai YS; Hsieh MY; Huang CI; Huang JF; Tsai PC; Hsi E; Juo SH; Tsai WL; Chuang WL; Yu ML; Dai CY
    J Mol Med (Berl); 2016 Mar; 94(3):311-20. PubMed ID: 26489607
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
    Laguno M; Von Wichmann MA; Van den Eynde E; Navarro J; Cifuentes C; Murillas J; Veloso S; Martínez-Rebollar M; Guardiola JM; Jou A; Gómez-Sirvent JL; Cervantes M; Pineda JA; López-Calvo S; Carrero A; Montes ML; Deig E; Tapiz A; Ruiz-Mesa JD; Cruceta A; de Lazzari E; Mallolas J
    Int J Infect Dis; 2016 Dec; 53():46-51. PubMed ID: 27815225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients.
    Tsubota A; Shimada N; Yoshizawa K; Furihata T; Agata R; Yumoto Y; Abe H; Ika M; Namiki Y; Chiba K; Fujise K; Tada N; Aizawa Y
    Liver Int; 2012 May; 32(5):826-36. PubMed ID: 22212648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantification of ENT1 and ENT2 Proteins at the Placental Barrier and Contribution of These Transporters to Ribavirin Uptake.
    Nishimura T; Sano Y; Takahashi Y; Noguchi S; Uchida Y; Takagi A; Tanaka T; Katakura S; Nakashima E; Tachikawa M; Maruyama T; Terasaki T; Tomi M
    J Pharm Sci; 2019 Dec; 108(12):3917-3922. PubMed ID: 31520644
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir.
    Vispo E; Barreiro P; Pineda JA; Mira JA; Maida I; Martín-Carbonero L; Rodríguez-Nóvoa S; Santos I; López-Cortes LF; Merino D; Rivero A; Soriano V
    Antivir Ther; 2008; 13(3):429-37. PubMed ID: 18572756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection.
    Grebely J; Hellard M; Applegate T; Petoumenos K; Yeung B; Feld JJ; Rawlinson W; Lloyd AR; George J; Kaldor JM; Dore GJ; Matthews GV;
    AIDS; 2012 Aug; 26(13):1653-61. PubMed ID: 22555168
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistence of HCV in quiescent hepatic cells under conditions of an interferon-induced antiviral response.
    Bauhofer O; Ruggieri A; Schmid B; Schirmacher P; Bartenschlager R
    Gastroenterology; 2012 Aug; 143(2):429-38.e8. PubMed ID: 22522091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sustained virologic response to standard interferon or pegylated interferon and ribavirin in patients with hepatitis C virus genotype 5: systematic review and meta-analysis of ten studies and 423 patients.
    Devaki P; Jencks D; Yee BE; Nguyen MH
    Hepatol Int; 2015 Jul; 9(3):431-7. PubMed ID: 26016464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy.
    Kondo Y; Ueno Y; Ninomiya M; Tamai K; Tanaka Y; Inoue J; Kakazu E; Kobayashi K; Kimura O; Miura M; Yamamoto T; Kobayashi T; Igarashi T; Shimosegawa T
    J Gastroenterol; 2012 Dec; 47(12):1323-35. PubMed ID: 22588246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.